Trastuzumab, a targeted monoclonal antibody against HER2, has been shown to improve survival outcomes in HER2-positive lobular breast cancer patients (Slamon et al., 2001; Tolaney et al., 2015). This evidence concerns the gene ERBB2 and Hereditary breast cancer.